Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | FAP | Q12884 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19302833 | 1.00 | EPHX1 (0.57) | EPHX1SMN1; SMN2HSD17B10NAAAHDAC8 | |
| SCHEMBL12019238 | 0.89 | KMT2A (0.48) | EPHX1SMN1; SMN2HSD17B10NAAAPSMB5 | |
| SCHEMBL12508317 | 0.82 | PSMB5 (0.44) | EPHX1SMN1; SMN2HSD17B10NAAAPSMB5 | |
| SCHEMBL1449384 | 0.81 | EPHX1 (0.59) | EPHX1SMN1; SMN2HSD17B10NAAAHDAC8 | |
| SCHEMBL15865900 | 0.81 | EPHX1 (0.59) | EPHX1SMN1; SMN2HSD17B10NAAAHDAC8 | |
| SCHEMBL6136977 | 0.80 | EPHX1 (0.63) | EPHX1SMN1; SMN2HSD17B10NAAAHDAC8 | |
| SCHEMBL13574437 | 0.80 | KMT2A (0.41) | EPHX1SMN1; SMN2HSD17B10NAAAPSMB5 | |
| SCHEMBL28367593 | 0.80 | EPHX2 (0.59) | EPHX1SMN1; SMN2HSD17B10NAAAHDAC8 | |
| SCHEMBL21558248 | 0.80 | PSMB5 (0.54) | EPHX1SMN1; SMN2HSD17B10NAAAHDAC8 | |
| SCHEMBL28095544 | 0.80 | EPHX2 (0.59) | EPHX1SMN1; SMN2HSD17B10NAAAHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | EPHX1 465/4885SMN1; SMN2 4207/4885HSD17B10 35/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | EPHX1 247/4885SMN1; SMN2 4287/4885HSD17B10 37/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | EPHX1 124/4885SMN1; SMN2 4370/4885HSD17B10 39/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | EPHX1 124/4885SMN1; SMN2 4370/4885HSD17B10 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.